In special populations with advanced non-small cell lung cancer (NSCLC), combining the PD-1 immune check point inhibitor nivolumab with the monoclonal antibody ipilimumab showed a consistent safety profile, stated research presented today by at the IASLC 2019 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer.
The research was presented by Dr. Fabrice Barlesi from Aix-Marseille University, Assistance Publique Hopitaux de Marseille, Marseille, France....
In special populations with advanced non-small cell lung cancer (NSCLC), combining the PD-1 immune check point inhibitor nivolumab with the monoclonal antibody ipilimumab showed a consistent safety profile, stated research presented today by at the IASLC 2019 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer.
The research was presented by Dr. Fabrice Barlesi from Aix-Marseille University, Assistance Publique Hopitaux de Marseille, Marseille, France....